Role of prophylactic extended field radiotherapy (EFRT) to para-aortic lymph node in pelvic lymph node positive locally advanced cervical cancer

Assessment of the role of prophylactic extended field radiotherapy (EFRT) in pelvic lymph node positive locally advanced cervical cancer: A prospective randomized control study. - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/09/058068

Enrollment

Registered

2023-09-27

Start date

Unknown

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified

Interventions

Intervention1: Prophylactic EFRT with concurrent chemotherapy -: Prophylactic EFRT with concurrent chemotherapy (Inj. Cisplatin 40 mg/m2 IV weekly during radiation) , SIB plan(45-50Gy , 1.8-2 Gy per

Eligibility

Inclusion criteria

Inclusion criteria: DIAGNOSED CASE OF CANCER CERVIX, IIIC1 STAGE (FIGO 2018) PATIENT WILLING TO TAKE PART IN STUDY

Exclusion criteria

Exclusion criteria: Medical contraindication for Chemo radiotherapy. Pregnancy Patient with prior chemotherapy history.

Design outcomes

Primary

Measure	Time frame
overall survival (OS), disease free survival (DFS) para-aortic lymph node metastases (PAO-LNM) Timepoint: To assess the overall survival (OS), disease free survival (DFS) and para-aortic lymph node metastases (PAO-LNM) at the end of 1st, 2nd and 3rd year.	—

Secondary

Measure	Time frame
Percentage of cases of IIIC1 LACC who gets upstaged post PET CT scan. To categories the acute & late toxicity related to chemo radiation according to RTOG/EORTC morbidity scoring scheme. To correlate the toxicities with the doses to OARs. Timepoint: Yearly for 3 year post chemoradiation.	—

Countries

India

Contacts

Public ContactDr Pritanjali Singh

AIIMS PATNA

drpritanjalis@gmail.com9334931395

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026